New sampling technique for detecting Barrett's esophagus recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Wide-Area Trans-Epithelial Sampling (WATS-3D) in improving the detection of recurrent Barrett's esophagus (BE) after endoscopic eradication therapy (EET). The study aims to compare the results of WATS-3D tissue sampling with traditional forceps biopsies to determine if the new method can reduce missed diagnoses of dysplasia and prevent progression to esophageal cancer. Participants will include adults diagnosed with BE who have achieved complete eradication of intestinal metaplasia. The trial will be conducted at multiple leading medical institutions across the United States.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients aged 18+ diagnosed with Barrett's esophagus with confirmed histologic dysplasia or intra-mucosal cancer undergoing surveillance after EET
* Patients who have achieved CE-IM on at least one surveillance endoscopy following EET
* All subjects must have given signed, informed consent prior to registration in the study

Exclusion Criteria:

* All patients who are unable or unwilling to give consent will not be included in the study
* All patients deemed to have refractory BE despite EET
* Patients who are pregnant, vulnerable populations such as prisoners, life expectancy \< 1 year based on concurrent comorbidities, coagulopathy with INR \> 1.5 that cannot be reversed, thrombocytopenia with platelets \< 125,000 that cannot be corrected with blood products, unable to safely undergo elective endoscopy due to current comorbidities, and inability to pass standard endoscope will not be included in the study

Where it's running

• Northwestern Memorial Hospital
  Chicago, Illinois, United States Recruiting
• University of California, LA
  Los Angeles, California, United States Not yet recruiting
• University of Colorado
  Aurora, Colorado, United States Not yet recruiting
• Washington University in St. Louis, Barnes Jewish Hospital
  Saint Louis, Missouri, United States Not yet recruiting

Study contacts

• Principal investigator: Srinadh Komanduri — Feinberg School of Medicine
• Study coordinator: Srinadh Komanduri, MD, MS
• Email: skomandu@nm.org
• Phone: 3126950484

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing breath and blood biomarkers for early detection of gastro-esophageal cancer

  This study is testing if breath and blood samples can help find early signs of gastro-esophageal cancer in people who are at risk.

  Recruiting KU Leuven · Leuven · NCT06346054

• Detecting early esophageal cancer using sponge cytology

  This study is testing if a sponge can help find early signs of esophageal cancer and Barrett's Esophagus in people having an endoscopy at Johns Hopkins Hospital.

  Recruiting at 2 sites Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT04214119

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.